264 related articles for article (PubMed ID: 32366710)
1. Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model.
Bilal H; Bergen PJ; Tait JR; Wallis SC; Peleg AY; Roberts JA; Oliver A; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366710
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301
[TBL] [Abstract][Full Text] [Related]
3. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
[TBL] [Abstract][Full Text] [Related]
4. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
Bilal H; Tait JR; Lang Y; Zhou J; Bergen PJ; Peleg AY; Bulitta JB; Oliver A; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0220321. PubMed ID: 35041509
[TBL] [Abstract][Full Text] [Related]
5. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
Breen SKJ; Harper M; López-Causapé C; Rogers KE; Tait JR; Smallman TR; Lang Y; Lee WL; Zhou J; Zhang Y; Bulitta JB; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
Int J Antimicrob Agents; 2024 Jun; 63(6):107161. PubMed ID: 38561094
[TBL] [Abstract][Full Text] [Related]
7. Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
Agyeman AA; López-Causapé C; Rogers KE; Lucas DD; Cortés-Lara S; Gomis-Font MA; Fraile-Ribot P; Figuerola J; Lang Y; Franklyn ERT; Lee WL; Zhou J; Zhang Y; Bulitta JB; Boyce JD; Nation RL; Oliver A; Landersdorfer CB
Int J Antimicrob Agents; 2023 Sep; 62(3):106887. PubMed ID: 37315906
[TBL] [Abstract][Full Text] [Related]
8. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm.
Benavent E; Ulldemolins M; El Haj C; Rigo-Bonnin R; Yu H; Wang L; Wickremasinghe H; Ariza J; Murillo O
Int J Antimicrob Agents; 2023 Aug; 62(2):106856. PubMed ID: 37211260
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model.
Tait JR; Bilal H; Kim TH; Oh A; Peleg AY; Boyce JD; Oliver A; Bergen PJ; Nation RL; Landersdorfer CB
J Glob Antimicrob Resist; 2021 Sep; 26():55-63. PubMed ID: 34023531
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
12. Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.
Tait JR; Harper M; Cortés-Lara S; Rogers KE; López-Causapé C; Smallman TR; Lang Y; Lee WL; Zhou J; Bulitta JB; Nation RL; Boyce JD; Oliver A; Landersdorfer CB
Antimicrob Agents Chemother; 2023 Aug; 67(8):e0041423. PubMed ID: 37428034
[TBL] [Abstract][Full Text] [Related]
13. Clinically Relevant Concentrations of Polymyxin B and Meropenem Synergistically Kill Multidrug-Resistant
Wickremasinghe H; Yu HH; Azad MAK; Zhao J; Bergen PJ; Velkov T; Zhou QT; Zhu Y; Li J
Antibiotics (Basel); 2021 Apr; 10(4):. PubMed ID: 33918040
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Srivastava P; Sivashanmugam K
Infect Genet Evol; 2021 Aug; 92():104824. PubMed ID: 33774177
[TBL] [Abstract][Full Text] [Related]
15. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1.
Riera E; Macià MD; Mena A; Mulet X; Pérez JL; Ge Y; Oliver A
J Antimicrob Chemother; 2010 Jul; 65(7):1399-404. PubMed ID: 20435779
[TBL] [Abstract][Full Text] [Related]
16. Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant Pseudomonas aeruginosa Clinical Isolates.
Karabasevic N; Roberts JA; Stronach L; Naicker S; Wallis SC; Sjövall F; Sime F
Antimicrob Agents Chemother; 2022 May; 66(5):e0214021. PubMed ID: 35389238
[TBL] [Abstract][Full Text] [Related]
17. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a ciprofloxacin/amikacin combination against planktonic and biofilm cultures of susceptible and low-level resistant Pseudomonas aeruginosa.
Soares A; Alexandre K; Lamoureux F; Lemée L; Caron F; Pestel-Caron M; Etienne M
J Antimicrob Chemother; 2019 Nov; 74(11):3252-3259. PubMed ID: 31424553
[TBL] [Abstract][Full Text] [Related]
19. Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model.
Avent ML; McCarthy KL; Sime FB; Naicker S; Heffernan AJ; Wallis SC; Paterson DL; Roberts JA
Microbiol Spectr; 2022 Jun; 10(3):e0052522. PubMed ID: 35442072
[TBL] [Abstract][Full Text] [Related]
20. Bacteriophage-antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa: In vitro synergy testing.
Holger DJ; Lev KL; Kebriaei R; Morrisette T; Shah R; Alexander J; Lehman SM; Rybak MJ
J Appl Microbiol; 2022 Sep; 133(3):1636-1649. PubMed ID: 35652690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
